

Asphyxia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

https://marketpublishers.com/r/A3E6489E3670EN.html

Date: May 2024

Pages: 138

Price: US\$ 6,499.00 (Single User License)

ID: A3E6489E3670EN

Abstracts

The 7 major asphyxia markets are expected to exhibit a CAGR of 11.36% during 2024-2034.

The asphyxia market has been comprehensively analyzed in IMARC's new report titled "Asphyxia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Asphyxia refers to a potentially life-threatening condition in which there is a severe shortage of oxygen flow to the body tissues, causing suffocation. As a result, it disrupts the regular functioning of critical organs, particularly the brain. The symptoms of the ailment include shortness of breath, rapid breathing, bluish discoloration of the skin, lips, or nails, dizziness, lightheadedness, tightness or discomfort in the chest, increased heart rate, sweating, a throbbing headache, etc. In some cases, individuals suffering from this illness may also experience impaired mental function, difficulty concentrating, feeling dazed, seizures, loss of consciousness, or even coma. The diagnosis of asphyxia involves a combination of clinical evaluation, medical history, and various diagnostic tests. A healthcare professional may also perform numerous imaging techniques, such as X-rays, computed tomography (CT), magnetic resonance imaging (MRI), etc., to identify structural abnormalities, injuries, or conditions affecting the airways, lungs, or brain. Additionally, pulse oximetry, a non-invasive test that measures the oxygen saturation levels in the blood, is utilized to support the diagnosis among patients.

The increasing cases of respiratory conditions, such as asthma, chronic obstructive pulmonary disease, pneumonia, etc., that cause airway blockages are primarily driving the asphyxia market. In addition to this, the rising incidences of exposure to toxic gases, including hydrogen sulfide and carbon monoxide, which can bind to the hemoglobin in



red blood cells, thereby disrupting their ability to utilize oxygen, are also creating a positive outlook for the market. Moreover, the widespread adoption of effective drugs, such as bronchodilators, muscle relaxants, anticonvulsants, etc., to reduce the symptoms and restore normal physiological functioning in the patients is further bolstering the market growth. Apart from this, the escalating application of hyperbaric oxygen therapy, since it increases the amount of oxygen dissolved in the bloodstream to significantly improve cellular metabolism, tissue regeneration, and the functions of vital organs, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of extracorporeal membrane oxygenation techniques for the treatment of severe disease conditions on account of their various advantages, like removing excess carbon dioxide from the blood while supporting the body's essential processes, is expected to drive the asphyxia market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the asphyxia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for asphyxia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the asphyxia market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023 Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy



Spain Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the asphyxia market
Historical, current, and future performance of various therapeutic categories in the
market

Sales of various drugs across the asphyxia market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current asphyxia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report: Market Insights

How has the asphyxia market performed so far and how will it perform in the coming



years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the asphyxia market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the asphyxia market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of asphyxia across the seven major markets?

What is the number of prevalent cases (2018-2034) of asphyxia by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of asphyxia by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with asphyxia across the seven major markets?

What is the size of the asphyxia patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of asphyxia? What will be the growth rate of patients across the seven major markets?

Asphyxia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance? What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for asphyxia drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the asphyxia market?

What are the key regulatory events related to the asphyxia market?



What is the structure of clinical trial landscape by status related to the asphyxia market? What is the structure of clinical trial landscape by phase related to the asphyxia market? What is the structure of clinical trial landscape by route of administration related to the asphyxia market?



Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 ASPHYXIA - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 ASPHYXIA - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 ASPHYXIA - EPIDEMIOLOGY AND PATIENT POPULATION

7.1 Epidemiology - Key Insights



- 7.2 Epidemiology Scenario Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (?2018-2034?)
 - 7.2.4 Epidemiology by Gender (?2018-2034?)
 - 7.2.5 Diagnosed Cases (?2018-2034?)
 - 7.2.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (?2018-2034?)
 - 7.3.4 Epidemiology by Gender (?2018-2034?)
 - 7.3.5 Diagnosed Cases (?2018-2034?)
 - 7.3.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (?2018-2034?)
 - 7.4.4 Epidemiology by Gender (?2018-2034?)
 - 7.4.5 Diagnosed Cases (?2018-2034?)
 - 7.4.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (?2018-2034?)
 - 7.5.4 Epidemiology by Gender (?2018-2034?)
 - 7.5.5 Diagnosed Cases (?2018-2034?)
 - 7.5.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (2018-2034)
 - 7.6.4 Epidemiology by Gender (?2018-2034?)
 - 7.6.5 Diagnosed Cases (?2018-2034?)
 - 7.6.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.7 Epidemiology Scenario Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)
 - 7.7.3 Epidemiology by Age (?2018-2034?)



- 7.7.4 Epidemiology by Gender (?2018-2034?)
- 7.7.5 Diagnosed Cases (?2018-2034?)
- 7.7.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (?2018-2034?)
 - 7.8.4 Epidemiology by Gender (?2018-2034?)
 - 7.8.5 Diagnosed Cases (?2018-2034?)
 - 7.8.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (?2018-2034?)
 - 7.9.4 Epidemiology by Gender (?2018-2034?)
 - 7.9.5 Diagnosed Cases (?2018-2034?)
 - 7.9.6 Patient Pool/Treated Cases (?2018-2034?)

8 ASPHYXIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 ASPHYXIA - UNMET NEEDS

10 ASPHYXIA - KEY ENDPOINTS OF TREATMENT

11 ASPHYXIA - MARKETED PRODUCTS

- 11.1 List of Asphyxia Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Drug Name Company Name
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.



12 ASPHYXIA - PIPELINE DRUGS

- 12.1 List of Asphyxia Pipeline Drugs Across the Top 7 Markets
 - 12.1.1 2-iminobiotin Neurophyxia
 - 12.1.1.1 Drug Overview
 - 12.1.1.2 Mechanism of Action
 - 12.1.1.3 Clinical Trial Results
 - 12.1.1.4 Safety and Efficacy
 - 12.1.1.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. ASPHYXIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. ASPHYXIA – CLINICAL TRIAL LANDSCAPE

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

15 ASPHYXIA - MARKET SCENARIO

- 15.1 Market Scenario Key Insights
- 15.2 Market Scenario Top 7 Markets
 - 15.2.1 Asphyxia Market Size
 - 15.2.1.1 Market Size (2018-2023)
 - 15.2.1.2 Market Forecast (2024-2034)
 - 15.2.2 Asphyxia Market Size by Therapies
 - 15.2.2.1 Market Size by Therapies (2018-2023)
 - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario United States
 - 15.3.1 Asphyxia Market Size
 - 15.3.1.1 Market Size (2018-2023)
 - 15.3.1.2 Market Forecast (2024-2034)
 - 15.3.2 Asphyxia Market Size by Therapies
 - 15.3.2.1 Market Size by Therapies (2018-2023)
 - 15.3.2.2 Market Forecast by Therapies (2024-2034)



- 15.3.3 Asphyxia Access and Reimbursement Overview
- 15.4 Market Scenario Germany
 - 15.4.1 Asphyxia Market Size
 - 15.4.1.1 Market Size (2018-2023)
 - 15.4.1.2 Market Forecast (2024-2034)
 - 15.4.2 Asphyxia Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (2018-2023)
 - 15.4.2.2 Market Forecast by Therapies (2024-2034)
 - 15.4.3 Asphyxia Access and Reimbursement Overview
- 15.5 Market Scenario France
 - 15.5.1 Asphyxia Market Size
 - 15.5.1.1 Market Size (2018-2023)
 - 15.5.1.2 Market Forecast (2024-2034)
 - 15.5.2 Asphyxia Market Size by Therapies
 - 15.5.2.1 Market Size by Therapies (2018-2023)
 - 15.5.2.2 Market Forecast by Therapies (2024-2034)
 - 15.5.3 Asphyxia Access and Reimbursement Overview
- 15.6 Market Scenario United Kingdom
 - 15.6.1 Asphyxia Market Size
 - 15.6.1.1 Market Size (2018-2023)
 - 15.6.1.2 Market Forecast (2024-2034)
 - 15.6.2 Asphyxia Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
- 15.6.3 Asphyxia Access and Reimbursement Overview
- 15.7 Market Scenario Italy
 - 15.7.1 Asphyxia Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034)
 - 15.7.2 Asphyxia Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
 - 15.7.3 Asphyxia Access and Reimbursement Overview
- 15.8 Market Scenario Spain
 - 15.8.1 Asphyxia Market Size
 - 15.8.1.1 Market Size (2018-2023)
 - 15.8.1.2 Market Forecast (2024-2034)
 - 15.8.2 Asphyxia Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)



- 15.8.2.2 Market Forecast by Therapies (2024-2034)
- 15.8.3 Asphyxia Access and Reimbursement Overview
- 15.9 Market Scenario Japan
 - 15.9.1 Asphyxia Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Asphyxia Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Asphyxia Access and Reimbursement Overview

16 ASPHYXIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 ASPHYXIA MARKET - SWOT ANALYSIS

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

18 ASPHYXIA MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX



I would like to order

Product name: Asphyxia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and

Forecast 2024-2034

Product link: https://marketpublishers.com/r/A3E6489E3670EN.html

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/A3E6489E3670EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

